Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRON NASDAQ:CVAC NASDAQ:HELP NASDAQ:SVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRONCronos Group$2.63-4.0%$2.59$1.84▼$3.43$989.59M0.871.46 million shs3.91 million shsCVACCureVac$4.66$4.66$3.13▼$5.72$1.05B1.77992,546 shsN/AHELPCybin$4.67-7.7%$5.14$4.29▼$9.83$241.11M0.8962,232 shs989,745 shsSVRASavara$5.03-4.6%$5.35$1.89▼$7.01$1.03B0.281.52 million shs2.51 million shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRONCronos Group+0.37%+6.61%+6.61%+5.38%+33.01%CVACCureVac0.00%0.00%0.00%0.00%+38.28%HELPCybin-2.32%-5.24%-7.33%-16.91%+505,999,900.00%SVRASavara0.00%+2.13%-13.18%-5.89%+76.25%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRONCronos Group$2.63-4.0%$2.59$1.84▼$3.43$989.59M0.871.46 million shs3.91 million shsCVACCureVac$4.66$4.66$3.13▼$5.72$1.05B1.77992,546 shsN/AHELPCybin$4.67-7.7%$5.14$4.29▼$9.83$241.11M0.8962,232 shs989,745 shsSVRASavara$5.03-4.6%$5.35$1.89▼$7.01$1.03B0.281.52 million shs2.51 million shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRONCronos Group+0.37%+6.61%+6.61%+5.38%+33.01%CVACCureVac0.00%0.00%0.00%0.00%+38.28%HELPCybin-2.32%-5.24%-7.33%-16.91%+505,999,900.00%SVRASavara0.00%+2.13%-13.18%-5.89%+76.25%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRONCronos Group 2.20Hold$2.30-12.55% DownsideCVACCureVac 1.80Reduce$6.8346.64% UpsideHELPCybin 3.00Buy$58.751,158.03% UpsideSVRASavara 2.78Moderate Buy$9.1381.41% UpsideCurrent Analyst Ratings BreakdownLatest HELP, SVRA, CVAC, and CRON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2026CRONCronos Group TD SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy4/24/2026SVRASavara OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$9.00 ➝ $11.004/21/2026SVRASavara Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/13/2026HELPCybin TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy3/16/2026SVRASavara William BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$10.003/16/2026SVRASavara HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy3/2/2026CRONCronos Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Sell (D+)3/2/2026HELPCybin HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$55.00 ➝ $95.002/24/2026CRONCronos Group TD SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRONCronos Group$146.59M6.75$0.01 per share217.76$2.99 per share0.88CVACCureVac$70.74M14.78$0.99 per share4.73$3.36 per share1.39HELPCybinN/AN/AN/AN/A$7.89 per shareN/ASVRASavaraN/AN/AN/AN/A$0.86 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRONCronos Group-$9.45M$0.01263.26N/AN/A-1.14%-1.26%-1.20%N/ACVACCureVac$175.50M$0.726.47N/AN/A199.92%-23.03%-19.09%N/AHELPCybin-$81.31M-$4.23N/AN/AN/AN/A-59.98%-50.80%N/ASVRASavara-$118.84M-$0.56N/AN/AN/AN/A-87.19%-66.42%N/ALatest HELP, SVRA, CVAC, and CRON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026SVRASavara-$0.14-$0.15-$0.01-$0.15$0.50 millionN/A5/11/2026Q1 2026CRONCronos Group$0.01$0.01N/A$0.04$42.20 million$58.97 million3/13/2026Q4 2025SVRASavara-$0.12-$0.13-$0.01-$0.13N/AN/A2/26/2026Q4 2025CRONCronos Group$0.01$0.02+$0.01N/A$38.51 million$58.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRONCronos GroupN/AN/AN/AN/AN/ACVACCureVacN/AN/AN/AN/AN/AHELPCybinN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRONCronos GroupN/A21.8718.62CVACCureVac0.033.703.69HELPCybinN/A13.7813.78SVRASavara0.1713.4711.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRONCronos Group8.71%CVACCureVac17.26%HELPCybin17.94%SVRASavara87.93%Insider OwnershipCompanyInsider OwnershipCRONCronos Group7.80%CVACCureVac2.15%HELPCybin15.00%SVRASavara5.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRONCronos Group450376.27 million346.92 millionOptionableCVACCureVac880224.34 million219.52 millionOptionableHELPCybin5051.63 million43.89 millionN/ASVRASavara20204.93 million194.06 millionOptionableHELP, SVRA, CVAC, and CRON HeadlinesRecent News About These CompaniesGuggenheim Reaffirms Their Buy Rating on Savara (SVRA)25 minutes ago | theglobeandmail.comSavara (SVRA) Receives a Buy from Piper Sandler25 minutes ago | theglobeandmail.comSavara Reports First Quarter Financial Results and Provides Business UpdateMay 12 at 4:05 PM | businesswire.comSavara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor ConferenceMay 12 at 12:30 PM | cadillacnews.comCSwedbank AB Has $5.13 Million Position in Savara Inc. $SVRAMay 10, 2026 | marketbeat.comNan Fung Trinity HK Ltd. Takes $10.18 Million Position in Savara Inc. $SVRAMay 10, 2026 | marketbeat.comSavara Inc. $SVRA Position Boosted by F m Investments LLCMay 10, 2026 | marketbeat.comSavara (SVRA) to Release Earnings on TuesdayMay 5, 2026 | marketbeat.comAssessing Savara (SVRA) Valuation After FDA Extends Priority Review For MolgramostimApril 26, 2026 | finance.yahoo.comSavara (NASDAQ:SVRA) Coverage Initiated by Analysts at OppenheimerApril 24, 2026 | marketbeat.comSavara Inc. (NASDAQ:SVRA) Given Average Recommendation of "Moderate Buy" by BrokeragesApril 21, 2026 | marketbeat.comFY2026 EPS Estimates for Savara Decreased by Lifesci CapitalApril 20, 2026 | marketbeat.comSavara (NASDAQ:SVRA) Strengthens Market Presence In Nasdaq Today Biotech SegmentApril 19, 2026 | kalkinemedia.comKSavara (NASDAQ:SVRA) Stock Price Up 2.5% - Here's WhyApril 17, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Savara (SVRA) and Rhythm Pharmaceuticals (RYTM)April 17, 2026 | theglobeandmail.comSavara Announces New Employment Inducement GrantApril 17, 2026 | businesswire.comSavara gets FDA review extension for lead assetApril 16, 2026 | seekingalpha.comSavara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application ...April 15, 2026 | uk.finance.yahoo.comSVRA stock slips post-market after FDA delays decision on pulmonary therapyApril 15, 2026 | msn.comSavara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)April 15, 2026 | businesswire.comSavara To Present New Data at the American Thoracic Society (ATS) 2026 International ConferenceApril 14, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026Before the Moon Base Gets Built, These 4 Companies WinBy Thomas Hughes | May 11, 2026Quantum Earnings Season Is Ramping Up—What to Watch From 2 Major PlayersBy Nathan Reiff | May 10, 2026$39 Trillion Debt Signal: 3 TIPS ETFs to Hedge Persistent InflationBy Chris Markoch | April 19, 20262 Ways to Play the Big Pharma Patent CliffBy Nathan Reiff | May 15, 2026HELP, SVRA, CVAC, and CRON Company DescriptionsCronos Group NASDAQ:CRON$2.63 -0.11 (-4.01%) Closing price 04:00 PM EasternExtended Trading$2.63 0.00 (-0.08%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.CureVac NASDAQ:CVAC$4.66 0.00 (0.00%) As of 05/14/2026CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.Cybin NASDAQ:HELP$4.67 -0.39 (-7.71%) Closing price 04:00 PM EasternExtended Trading$4.70 +0.03 (+0.54%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a discovery-phase phenethylamine derivative to treat neuroinflammation and psychiatric conditions. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.Savara NASDAQ:SVRA$5.03 -0.24 (-4.55%) Closing price 04:00 PM EasternExtended Trading$5.19 +0.16 (+3.16%) As of 05:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Datavalut Gains Traction: 5 Reasons to Sell Now TMC Stock: Why This Pre-Revenue Miner Is Worth Watching Viking Sails to All-Time Highs—Fundamentals Signal More to Come YETI Rallies After Earnings Beat and Raised Outlook Aeluma's Post-Earnings Dip Creates a Buying Opportunity Cisco’s Vertical Rally May Still Be in the Early Innings Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs McDonald's Is the Cheapest It’s Been in Years—Does That Make It a Buy? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
